Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.

摘要: Although crizotinib has demonstrated promising efficacy and acceptable toxicity in patients with advanced non-small cell lung cancer (NSCLC), the available evidence Chinese populations is currently limited. This study compared progression-free survival (PFS) of anaplastic lymphoma kinase (ALK)-positive, adenocarcinoma who received first-line therapy that standard chemotherapy, also PFS benefit versus second-line treatment. Data on 80 ALK-positive, or chemotherapy as treatments between June 2013 December 2014 were retrospectively collected; 26 after progressive disease (PD) occurred chemotherapy. Tumor responses assessed using Response Evaluation Criteria Solid Tumors (RECIST), version 1.1. The median was 13.3 months (95% CI: 6.5-20.0 months) 5.4 months 4.4-6.5 months) (adjusted hazard ratio for progression death crizotinib, 0.20; 95% 0.11-0.36; P < 0.001). In therapy, 9.9 months 6.4-13.4 months). difference treatment not statistically significant progression, 0.56; 0.29-1.11; P = 0.092). Thus, there a ALK-positive adenocarcinoma. Additionally, showed it PD had